[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
Nov 26, 2012

Will Newer Anticoagulants Improve Therapy Persistence?Comment on “Persistence With Therapy Among Patients Treated With Warfarin for Atrial Fibrillation”

Author Affiliations

Author Affiliations: Department of Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy, University of South Carolina Campus, Columbia (Dr Maxwell); and South Carolina and the Hollings Cancer Center, Charleston (Dr Bennett).

Arch Intern Med. 2012;172(21):1689-1690. doi:10.1001/2013.jamainternmed.616

A trial fibrillation (AF) continues to be a leading cause of cerebrovascular morbidity and mortality resulting from cardioembolic stroke. When used appropriately, oral anticoagulation therapy has been shown to decrease the incidence of cardioembolic stroke in patients with AF by 50% to 60%.1 Appropriate use of warfarin anticoagulation requires precise adherence and monitoring to optimize the risk to benefit ratio associated with therapy and to ensure that therapy can be safely continued throughout the prescribed duration.

First Page Preview View Large
First page PDF preview
First page PDF preview
×